Key Drivers
- Liquidity Cushion
- Operating Losses
- Financing Dependence
AIAI Summary
IDYA has shifted from a speculative oncology platform to a near-term regulatory/launch story after registrational uveal melanoma data and an NDA under RTOR, but the stock likely won't re-rate meaningfully until approval, label clarity, and early commercial traction are proven amid heavy cash burn and dilution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Cushion
- •Operating Losses
- •Financing Dependence
IDYA has a strong liquidity cushion with $1.24B in cash/investments and very low debt, but persistent losses, negative free cash flow, and financing-driven cash inflows signal a high-risk, pre-breakeven profile.
Price Behavior
Key Price Behavior Insights:
- •Support holding
- •Resistance stall
- •Tight trading range
Over the last month, IDYA is range-bound with a slight positive tilt, holding $35.40-$35.00 support but stalling near $37.00 resistance.
Quick bounce from $35.40 to $37.02, then pulled back to $36.30
Sentiment & News
Key News Insights:
- •Uveal melanoma win
- •IDE892 expansion
- •Cash runway strong
IDEAYA Biosciences is delivering multiple oncology pipeline wins, led by a positive registrational trial readout, advancing IDE892 development, a new Roche collaboration, and a strong cash runway into 2030.
The news is materially positive for IDEAYA, reinforcing clinical execution, partnership optionality, and long-term funding visibility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings